Sign in
CompletedNo phase

Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
162 people enrolled
Started
4 Oct 2021
Ended
8 Aug 2024
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cardiac Magnetic Resonance, Blood Tests
Record updated
11 May 2025

Who can take part

Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Recovered COVID-19 patients; Definition of recovered COVID-19 patient:
  • COVID-19 diagnosis = established by a positive reverse transcription polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 [SARS-CoV2] and recovered from COVID-19
  • Recovery = based on two criteria: (1) two negative nasopharyngeal swab RT-PCR results >24 hours apart and (2) absence of fever and improvement in respiratory symptoms; Recovered non-COVID-19 patients with viral respiratory infections confirmed with viral polymerase chain reaction testing AND with a confirmed negative COVID-19 RT-PCR test; Age and gender matched controls with no cardiac risk factors, not on cardiac medications, no history of myocardial infarction, heart failure or myocarditis, negative COVID-19 RT-PCR test and negative COVID-19 antibodies test; Vaccination controls who planning to receive a 2-dose COVID-19 vaccine, with no history of myocardial infarction, heart failure or myocarditis AND with a confirmed negative COVID-19 RT-PCR test

Who cannot take part

  • Previous myocardial infarction or myocarditis unrelated to COVID-19 infection
  • History of heart failure unrelated to COVID-19 infection
  • Presence of pacemakers or implantable cardiac defibrillators
  • Limited life expectancy <1 year, for example due to pulmonary disease, cancer or significant hepatic failure
  • Renal impairment with eGFR <45ml/min/1.73m2
  • Any contraindication for CMR testing
  • Refusal or inability to sign an informed consent
  • Potential for non-compliance towards the requirements in the trial protocol (especially the medical treatment) or follow-up visits

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Introduction:

Read full original descriptionShow less

Coronavirus disease 2019 (COVID-19) remains a major health issue resulting in >800,000 deaths as of 30th August 2020. A concerning discovery of COVID-19 is the involvement of the myocardium. Several case studies including one from our group (recent study publication in JACC Cardiovascular Imaging led by the principal investigator of this grant application) have demonstrated subclinical myocardial inflammation in patients using cardiac magnetic resonance imaging (CMR) who have recovered from COVID-19. Furthermore at a cellular level, a recent autopsy study indicated that the severe acute respiratory syndrome coronavirus-2 is present in the myocardial tissue. The study further described invasion and viral progeny occurring in the myocardial interstitial cells and as such is a concerning development with the longer-term implications being unknown. These concerns have been noticed by the cardiology and non-cardiology medical community, with some expressing concerns of a new cause for cardiomyopathy and heart failure secondary to COVID-195. Therefore, it is critical that further studies are conducted to determine the longer-term outcome for patients.

The 4 groups in the trial

  • Recovered COVID-19 patientsExisting treatment, for comparison

    Recovered COVID-19 Patients will undergo three CMR examinations. The scans will take place at (i) within 2 weeks of confirmed recovery, (ii) 3 months after recovery and (iii) 1 year after recovery. At time of CMR examinations, patients will have blood tests.

    Treatment: Cardiac Magnetic Resonance, Blood Tests

  • non-COVID-19 patients with viral respiratory infectionsTreatment being tested

    non-COVID-19 Patients will undergo three CMR examinations. The scans will take place at (i) within 2 weeks of confirmed recovery, (ii) 3 months after recovery and (iii) 1 year after recovery. At time of CMR examinations, patients will have blood tests.

    Treatment: Cardiac Magnetic Resonance, Blood Tests

  • Volunteers as age and gender matched controls.Treatment being tested

    Volunteer controls will undergo one CMR examination. At time of CMR examinations, patients will have blood tests.

    Treatment: Cardiac Magnetic Resonance, Blood Tests

  • Volunteers who planning to receive a 2-dose COVID-19 vaccine as vaccination controlsTreatment being tested

    Vaccination controls will undergo two CMR examinations. The scans will take place (i) within 2 weeks before received 1st dose of COVID-19 vaccine and (ii) within 2 weeks (preferably 5-7 days) after receiving the 2nd dose of COVID-19 vaccine. At time of CMR examinations, patients will have blood tests.

    Treatment: Cardiac Magnetic Resonance, Blood Tests

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
11 May 2025